MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MTVA MetaVia Inc

休市中 07-10 16:00:00 EDT

1.78

+0.05

+2.89%

盘后1.76

-0.02-1.12%

19:59 EDT

最高1.80	最低1.65	成交量13.34万
今开1.74	昨收1.73	日振幅8.67%
总市值919.26万	流通市值601.91万	总股本516.44万
成交额23.05万	换手率3.94%	流通股本338.15万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.78,"timestamp":1783713600000,"preClose":1.73,"halted":0,"volume":133371,"hourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.78,"latestTime":"19:59 EDT","volume":15586,"amount":27485.1526,"timestamp":1783727947034,"change":-0.02,"changeRate":-0.011236,"amplitude":0.033708},"delay":0,"changeRate":0.02890173410404627,"floatShares":3381500,"shares":5164400,"eps":-2.541,"marketStatus":"休市中","change":0.05,"latestTime":"07-10 16:00:00 EDT","open":1.74,"high":1.8,"low":1.65,"amount":230475.0374766,"amplitude":0.086705,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.541,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.73,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.73,"latestTime":"09:28 EDT","volume":9869,"amount":17328.6188553,"timestamp":1783690117047,"change":0.02,"changeRate":0.011561,"amplitude":0.05185},"postHourTrading":{"tag":"盘后","latestPrice":1.76,"preClose":1.78,"latestTime":"19:59 EDT","volume":15586,"amount":27485.1526,"timestamp":1783727947034,"change":-0.02,"changeRate":-0.011236,"amplitude":0.033708},"volumeRatio":0.8378295244841351},"requestUrl":"/m/hq/s/MTVA/tweets","defaultTab":"tweets","newsList":[{"id":"1125748257","title":"MetaVia Inc宣布完成Da-1726治疗肥胖症1期第3部分研究的剂量滴定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125748257","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125748257?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:31","pubTimestamp":1783600310,"startTime":"0","endTime":"0","summary":"MetaVia Inc宣布，其用于治疗肥胖症的药物Da-1726，在1期临床试验的第3部分研究中，已成功完成剂量滴定阶段。这一进展标志着该药物研发过程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144525325","title":"MetaVia股东批准反向股票分割，比例介于1比5至1比22之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1144525325","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144525325?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:05","pubTimestamp":1780949115,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件，MetaVia Inc的股东已批准一项反向股票分割计划，具体执行比例将在1比5至1比22的范围内确定。\n该反向分割的最终比例将由公司董事会酌情决定，旨在提升每股股价，并可能满足相关证券交易所的持续上市要求。这一举措通常被股价长期低于规定门槛的公司所采用。\n股东授权董事会在此范围内实施反向分割，无需进一步征得股东同意。公司预计将在确定具体比例与生效日期后发布进一步公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171139494","title":"MetaVia在EASL 2026大会上公布DA-1726更高剂量一期结果，支持其在肥胖与MASH领域的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1171139494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171139494?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:31","pubTimestamp":1779885096,"startTime":"0","endTime":"0","summary":"MetaVia公司在2026年欧洲肝脏研究学会（EASL）大会上，公布了其候选药物DA-1726更高剂量组的一期临床试验结果。新数据进一步支持了该药物在治疗肥胖及代谢相关脂肪性肝炎（MASH）方面的潜在应用价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108786766","title":"Metavia启动Da-1726高剂量一期临床研究 首位肥胖症患者接受GLP-1/胰高血糖素双激动剂给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1108786766","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108786766?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:30","pubTimestamp":1775824246,"startTime":"0","endTime":"0","summary":"生物制药公司Metavia近日宣布，其针对肥胖症治疗的GLP-1与胰高血糖素双靶点激动剂Da-1726已完成高剂量组一期临床试验的首例患者给药。该研究旨在评估药物在提升剂量水平下的安全性与耐受性，标志着这款代谢疾病疗法开发取得重要阶段性进展。Da-1726通过同时激活GLP-1和胰高血糖素受体，有望在控制血糖的同时增强能量消耗，为肥胖治疗提供新机制方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187742668","title":"MetaVia获IRB批准推进DA-1726高剂量一期试验 GLP-1/胰高血糖素双激动剂展现最佳减重与血糖控制潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1187742668","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187742668?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:03","pubTimestamp":1773835407,"startTime":"0","endTime":"0","summary":"MetaVia Inc宣布，其核心肥胖治疗项目DA-1726获得机构审查委员会批准，将开展更高剂量的第一阶段临床试验。DA-1726是一种GLP-1与胰高血糖素双受体激动剂，临床前数据显示其在减重和血糖控制方面具备同类最佳潜力。DA-1726通过同时激活GLP-1和胰高血糖素受体，模拟肠道激素的自然作用。MetaVia计划在本季度内启动高剂量组的一期临床试验，重点评估DA-1726在健康受试者中的安全性、耐受性及药代动力学特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616036393","title":"Metavia Inc.盘中异动 下午盘急速上涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616036393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616036393?lang=zh_cn&edition=full","pubTime":"2026-03-03 03:37","pubTimestamp":1772480262,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日03时37分，Metavia Inc.股票出现波动，股价快速上涨5.30%。截至发稿，该股报1.59美元/股，成交量4.7403万股，换手率1.43%，振幅5.30%。Metavia Inc.股票所在的生物技术行业中，整体跌幅为0.34%。Metavia Inc.公司简介：MetaVia Inc是一家临床阶段的生物技术公司，专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030303374297a7b44c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030303374297a7b44c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MTVA","OXM","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614461177","title":"Metavia Inc.盘中异动 股价大涨5.30%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614461177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614461177?lang=zh_cn&edition=full","pubTime":"2026-02-24 23:04","pubTimestamp":1771945446,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日23时04分，Metavia Inc.股票出现异动，股价快速拉升5.30%。截至发稿，该股报1.59美元/股，成交量7123股，换手率0.21%，振幅2.07%。Metavia Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Metavia Inc.公司简介：MetaVia Inc是一家临床阶段的生物技术公司，专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423040697a6e1bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423040697a6e1bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MTVA","OXM","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150245570","title":"MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1150245570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150245570?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:06","pubTimestamp":1770210383,"startTime":"0","endTime":"0","summary":"MetaVia Inc公布其与Syntekabio持续合作中人工智能建模研究的积极成果。最新数据证实，双方共同开发的糖尿病肾病治疗药物Vanoglipel已通过AI模型精准锁定关键治疗靶点。\n这项突破性进展标志着AI驱动药物研发模式在复杂疾病领域的应用迈出重要一步。通过深度学习算法分析海量生物医学数据，研究团队成功验证了Vanoglipel作用于肾脏纤维化与炎症通路的核心机制。\n合作双方表示，该成果将显著加速Vanoglipel的临床前开发进程。AI建模不仅缩短了传统靶点确认周期，更通过多维度模拟预测了化合物与靶点相互作用的特异性，为后续药物优化提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metaviatx.com","stockEarnings":[{"period":"1week","weight":0.2027},{"period":"1month","weight":-0.0918},{"period":"3month","weight":0.2624},{"period":"6month","weight":-0.7817},{"period":"1year","weight":-0.7746},{"period":"ytd","weight":-0.7886}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MetaVia Inc.于2014年10月根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发用于治疗心血管代谢疾病的新型药物，其主要项目针对代谢功能障碍相关脂肪性肝炎和肥胖症。其研发管线包括GPR119激动剂vanoglipel和oxyntomodulin类似物双重激动剂DA-1726。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031121},{"month":4,"riseRate":0.4,"avgChangeRate":-0.109498},{"month":5,"riseRate":0.3,"avgChangeRate":-0.001142},{"month":6,"riseRate":0.5,"avgChangeRate":0.031858},{"month":7,"riseRate":0.3,"avgChangeRate":0.000635},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}